Cassava Sciences (SAVA)
(Real Time Quote from BATS)
$13.07 USD
+0.32 (2.51%)
Updated Jul 26, 2024 09:48 AM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Cassava Sciences, Inc. [SAVA]
Reports for Purchase
Showing records 61 - 80 ( 127 total )
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 112122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 111122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Revision - We Maintain Our Sell, and $12 Price Target for SAVA
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Simufilam Enrollment Remains on Track Across Alzheimer?s Disease Studies; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
3Q22 Review: Maintain SELL but Raising Price Target to $12 from $8, as Phase 3 Enrollment Increases
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 11122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 102122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Second Open-Label Study Initiated for Phase 3: Maintain SELL, $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 101122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 10122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 92122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 91122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 9122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 82122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Journal Publication Concludes No Data Manipulation; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Cassava Slowly Continues to Enroll Patients, Open-Label Improvements Down: $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 81122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Slow Enrollment Continues, Open-Label Interim Data Does Not Look Promising
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
A Gem Emerges in 12-Month Open-Label Study Data; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 8122
Provider: Stock Traders Daily
Analyst: Research Department